The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2018 Planned number of patients changed from 200 to 500.
- 16 Nov 2015 Planned primary completion date changed from 1 Sep 2025 to 1 Nov 2025 as reported by ClinicalTrials.gov record.